Biodesix Closes on $20M in Structured Debt Financing | GenomeWeb

Biodesix said this week that it has closed a structured debt financing with Capital Royalty Partners that provides the company with up to $20 million.

The funds will be used for ongoing development of Biodesix's technology platform and expansion of sales and marketing efforts in support of its VeriStrat proteomic test for guiding therapy in non-small cell lung cancer, the company said.

The deal follows the close by Biodesix in January of a $14.4 million Series E funding round.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.